Age Related Macular Degeneration News and Research

RSS
Polypoidal choroidal vasculopathy shows distinct classification

Polypoidal choroidal vasculopathy shows distinct classification

RPE transdifferentiation revealed in AMD

RPE transdifferentiation revealed in AMD

ORT incidence increases in nAMD despite anti-VEGF treatment

ORT incidence increases in nAMD despite anti-VEGF treatment

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Leica Microsystems to acquire OCT company Bioptigen

Leica Microsystems to acquire OCT company Bioptigen

New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics reports financial results for first quarter 2015

Anti-VEGF therapy benefits in wet AMD not sustained

Anti-VEGF therapy benefits in wet AMD not sustained

Submacular air injection aids tPA haemorrhage displacement

Submacular air injection aids tPA haemorrhage displacement

Heavy metallic elements influence AMD progression

Heavy metallic elements influence AMD progression

AMD severity and progression tracks across eyes

AMD severity and progression tracks across eyes

No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.